PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media287550ArticlesСтатьиResearch ArticleIntrakranial'nyy ateroskleroz: klinicheskie proyavleniya i podkhody k terapiiИнтракраниальный атеросклероз: клинические проявления и подходы к терапииDomashenkoM. AДомашенкоМ. А

к.м.н., с.н.с. 2-го неврологического отделения

mdomashenko@gmail.comLoskutnikovM. AЛоскутниковМ. А

к.м.н., врач-невролог 2-го неврологического отделения

GafarovaM. EГафароваМ. Э

аспирант

MaksimovaM. YuМаксимоваМ. Ю

д.м.н., проф., зав. 2-м неврологическим отделением

ФГБУ «Научный центр неврологии» РАМН, Москва101020142119NO19 (2014)№19 (2014)687326022023Copyright ©; 2014, Bionika MediaCopyright ©; 2014, ООО «Бионика Медиа»2014Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/287550

Intracranial atherosclerosis is one of the most common causes of ischemic cerebrovascular insufficiency worldwide. The article provides an overview of major international multi-center studies evaluating the efficacy and safety of different modes of monotherapy with antiplatelets and oral anticoagulants for the prevention of ischemic stroke. Along with measures for prevention of vascular events, it is recommended to include the Actovegin in the treatment regimen of patients with intracranial atherosclerosis as a drug contributing to the relief of the manifestations of cerebrovascular insufficiency and improvement of general state of patients with cerebrovascular insufficiency.

Интракраниальный атеросклероз является одной из наиболее частых причин ишемической недостаточности мозгового кровообращения во всем мире. В статье приведен обзор крупных международных многоцентровых исследований, оценивавших эффективность и безопасность различных режимов моно терапии антиагрегантами и пероральными антикоагулянтами с целью профилактики ишемического инсульта. Рекомендовано включение Актовегина в схему лечения пациентов с интракраниальным атеросклерозом наряду с мерами по профилактике сосудистых событий в качестве средства, способствующего нивелированию проявлений недостаточности мозгового кровообращения и улучшению самочувствия пациентов с недостаточностью мозгового кровообращения.

intracranial atherosclerosiscerebrovascular insufficiencyActoveginинтракраниальный атеросклерознедостаточность мозгового кровообращенияАктовегинArenillas J.F. Intracranial atherosclerosis: current concepts. Stroke. 2011; 42(Suppl 1): S20-3.De Silva D.A., Woon F.P., Lee M.P., et al. South Asian patients with ischemic stroke: intracranial large arteries are the predominant site of disease. Stroke. 2007; 38: 2592-94.Sacco R.L., Kargman D.E., Gu Q., Zamanillo M.C. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke. 1995; 26: 14-20.Wong K.S., Huang Y.N., Gao S., et al. Intracranial stenosis in Chinese patients with acute stroke. Neurology. 1998; 50: 812-13.Turan T.N., Cotsonis G., Lynn M.J., et al. Intracranial stenosis: impact of randomized trials on treatment preferences of US neurologists and neurointerventionists. Cerebrovasc dis. 2014; 37(3): 203-11.Gorelick P.B., Wong K.S., Bae H.J., Pandey D.K. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke. 2008; 39: 2396-99.Qureshi A.I., Safdar K., Patel M., et al. Stroke in young black patients. Risk factors, subtypes, and prognosis. Stroke. 1995; 26: 1995-98.Weisberg L.A. Clinical characteristics of transient ischemic attacks in black patients. Neurology. 1991; 41: 1410-14.Wityk R.J., Lehman D., Klag M., et al. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke. 1996; 27: 1974-80.Wong L.K. Global burden of intracranial atherosclerosis. Int. J. Stroke. 2006; 1: 158-59.Chimowitz M.I., Lynn M.J., Howlett-Smith H., et al. Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 2005; 352: 1305-16.Kasner S.E., Chimowitz M.I., Lynn M.J., et al.; for the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation. 2006; 113: 555-63.The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. N. Engl. J. Med. 1985; 313: 1191-200.Carvalho M., Oliveira A., Azevedo E., BastosLeite A.J. Intracranial arterial stenosis. J. Stroke. Cerebrovasc. Dis. 2014; 23(4): 599-609.Sanchez-Sanchez C., Egido J.A., Gonzalez-Gutierrez J.L. et al. Stroke and intracranial stenosis: clinical profile in a series of 134 patients in Spain. Rev. Neurol. 2004; 39: 305-11.Mazighi M., Labreuche J., Gongora-Rivera F., et al. Autopsy prevalence of intracranial atherosclerosis in patients with fatal stroke. Stroke. 2008; 39: 1142-47.Гулевская Т.С., Моргунов В.А. Патологическая анатомия нарушений мозгового кровообращения при атеросклерозе и артериальной гипертонии. М.: Медицина, 2009.Lee P.H., Oh S.H., Bang O.Y., et al. Infarct patterns in atherosclerotic middle cerebral artery versus internal carotid artery disease. Neurology. 2004; 62: 1291-96.Pu Y., Dou X., Liu L. Natural history of intracranial atherosclerotic disease. Front Neurol. 2014; 5: 125.Joon Kim B., Hong K.S., Cho Y.J., et al. Predictors of Symptomatic and Asymptomatic Intracranial Atherosclerosis: What is Different and Why? J. Atheroscler. Thromb. 2014; 21(6): 605-17.Holmstedt C.A., Turan T.N., Chimowitz M.I. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2013; 12(11): 1106-14.Willinsky R.A., Taylor S.M., TerBrugge K., et al. Neurologic complications of cerebral angiography: prospective analysis of 2 899 procedures and review of the literature. Radiology. 2003; 227: 522-28.Feldmann E., Wilterdink J.L., Kosinski A., et al. The Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) trial. Neurology. 2007; 68: 2099-106.Давыденко И.С., Кротенкова М.В., Коновалов Р.Н., Пирадов М.А. Проспективное сравнение компьютерно-томографической ангиографии, магнитно-резонансной ангиографии и дигитальной субтракционной ангиографии для определения степени гемодинамически значимых стенозов внутренних сонных артерий. Анналы клинической и экспериментальной неврологии. 2008; 3: 19-24.Bash S., Villablanca J.P., Jahan R., et al. Intracranial vascular stenosis and occlusive disease: evaluation with CT angiography, MR angiography, and digital subtraction angiography. AJNR Am. J. Neuroradiol. 2005; 26: 1012-21.Nguyen-Huynh M.N., Wintermark M., English J., et al. How accurate is CT angiography in evaluating intracranial atherosclerotic disease? Stroke. 2008; 39: 1184-88.Klein I.F., Lavalle'e P.C., Mazighi M., et al. Basilar artery atherosclerotic plaques in paramedian and lacunar pontine infarctions: a high-resolution MRI study. Stroke. 2010; 41: 1405-409.Turan T.N., Cotsonis G., Lynn M.J., et al.; for the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation. 2007; 115: 2969-75Chaturvedi S., Turan T.N., Lynn M.J., et al. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology. 2007; 69: 2063-68.Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008/2009 http://www.eso-stroke.org/recommendationsKernan W.N., Ovbiagele B., Black H.R., et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemick attack. A Guideline for healthcare prifessionals from the American Heart Association/American Stroke Association. Stroke 2014: published online May 1, 2014.Turan T.N., Maidan L., Cotsonis G., et al.; for the WASID Investigators. Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. Stroke. 2009; 40: 505-09.Kwon S.U., Cho Y.J., Koo J.S., et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis. Stroke. 2005; 36: 782-86.Kwon S.U., Hong K.S., Kang D.W., et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke. 2011; 42: 2883-90.Wang X., Lin W.H., Zhao Y.D., et al. and the CLAIR Study Investigators. The effectiveness of dual antiplatelet treatment in acute ischemic stroke patients with intracranial arterial stenosis: a subgroup analysis of CLAIR study. Int. J. Stroke. 2013; 8: 663-68.Teleb M.S., Asif K., Castonguay A.C., Zaidat O.O. Endovascular management of intracranial atherosclerosis. Neurosurg. Clin. N. Am. 2014; 25(3): 593-605.Chimowitz M.I., Lynn M.J., Derdeyn C.P., et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis [published correction appears in N. Engl. J. Med. 2012; 367: 93]. N. Engl. J. Med. 2011; 365: 993-1003.Derdeyn C.P., Chimowitz M.I., Lynn M.J., et al. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in highrisk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014; 383(9914): 333-41.Fiorella D., Derdeyn C.P., Lynn M.J., et al.; for the SAMMPRIS Trial Investigators. Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Stroke. 2012; 43: 2682-88.Herrmann W.M., Bohn-Olszewsky W.J., Kuntz G. Infusionstherapie mit Actovegin bei Patienten mit ptimar degenerativer Demenz vom Alzheimer Typ und Multiinfarkt Demenz. Z. Geriatrie. 1992; 5: 46-55.Остроумова О.Д., Галеева Н.Ю., Первичко Е.И. Коррекция когнитивных нарушений Актовегином у больных гипертонической болезнью. Мед. Алфавит. 2012; 4: 4-8.Михайлова Н.М., Селезнева Н.Д., Калын Я.Б., Рощина И.Ф., Гаврилова С.И. Эффективность лечения актовегином больных пожилого возраста с синдромом мягкого когнитивного снижения сосудистого генеза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013; 7: 69-76.Чуканова Е.И. Актовегин в лечении больных с дисциркуляторной энцефалопатией. Фарматека. 2005; 17: 71-5.Захаров В.В., Соснина В.Б. Применение антигипоксантов в лечении когнитивных нарушений у больных с сахарным диабетом. Неврологический журнал. 2008; 5: 39-43.